CEO Michael Herrera announced today that MHA Consulting has been retained by a leading international biotech company specializing in the research and development of antibody therapeutics for the treatment of cancer to assist with the ongoing development of their IT Disaster Recovery program. “The company’s proprietary product pipeline and next-generation antibody technologies are the results of a strong company culture and a deep passion for innovation,” said Herrera. “We are looking forward to working with them to ensure the availability of key operations during a disaster.”
MHA Consulting has been proud to serve organizations in the biotechnology sector from all over the United States for many years. This depth of experience provides us with unmatched knowledge among our peers and arms us with an understanding of the intricacies of the professional services arena. We look forward to being a trusted adviser to this organization, providing them with a sound foundation for risk mitigation, continuity, and resiliency that their BCM program follows the highest industry standards and best practices.
About MHA: A privately held company located in Phoenix, Arizona, MHA is a proven leader in Business Continuity Planning, Disaster Recovery Planning, IT best practices, and data center moves. Since 1999, we have helped protect trillions of dollars in global-market assets across an expansive range of companies and industries in the United States and abroad. MHA provides Business Continuity Management services that offer solutions that assist organizations with the analysis, development, implementation, and ongoing performance of plans that ensure the availability of critical business processes and Information Technology systems. We assist our clients in maintaining continuous operation of their critical business processes and IT resources – as well as meeting compliance requirements, reducing risk, and instilling investor confidence – all through effective and efficient continuity planning and execution.
